Revvity, Inc. has introduced the IDS i20™, a cutting-edge analytical random access platform developed by EUROIMMUN. This CE marked and FDA listed instrument offers full automation for chemiluminescence immunoassays (ChLIA), enabling laboratories to consolidate multiple specialty tests on a single device with enhanced reagent capacity and throughput.

Key Features:

• Simultaneous processing of 20 analytes across six diagnostic specialties

• Throughput of up to 140 tests per hour (assay dependent)

• Continuous loading of samples and reagents

• Integrated cooling for ready-to-use reagent cartridges

• State-of-the-art software with superior graphical user interface

• Compact design suitable for various laboratory environments

The IDS i20™ platform represents a significant advancement in laboratory automation, offering versatility and efficiency for specialty testing. Its high-throughput capabilities and user-friendly design make it a valuable addition to modern laboratories.